Clinical Trial Update: A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804 [Phase 1]

View source ↗

Summary

A Phase 1 study of PF-00299804 (dacomitinib) in patients with Non-Small Cell Lung Cancer to evaluate molecular changes after short-term exposure; the trial is t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PF-00299804

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: TERMINATED